



REVIEW

Bilingual edition English/Spanish

Drug-drug interactions in patients undergoing hematopoietic stem cell transplantation: systematic review

Interacciones farmacológicas en pacientes sometidos a trasplante de progenitores hematopoyéticos: revisión sistemática

María Sáez-Garrido, Alberto Espuny-Miró, Agustina Ruiz-Gómez, María Sacramento Díaz-Carrasco

Department of Pharmacy, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar (Murcia). Spain.

Author of correspondence

María Sáez Garrido
Servicio de Farmacia
Hospital Clínico Universitario
Virgen de la Arrixaca
Ctra. Cartagena, s/n
30120 El Palmar (Murcia). Spain.

Email:
mariasaez_15@hotmail.com

Received 27 December 2020;
Accepted 15 March 2021.
DOI: 10.7399/fh.11627

How to cite this paper

Sáez-Garrido M, Espuny-Miró A, Ruiz-Gómez A, Díaz-Carrasco MS. Drug-drug interactions in patients undergoing hematopoietic stem cell transplantation: systematic review. Farm Hosp. 2021;45(4):184-92.

Abstract

Objective: The present paper provides a systematic review aimed at identifying studies on pharmacological interactions in patients undergoing hematopoietic stem cell transplantation. Secondary objectives include a characterization of the prevalence of such interactions and an investigation of their specific characteristics.

Method: A search was performed of the terms "drug-drug interaction", "drug interaction", "stem cell transplant", "transplantation conditioning", "conditioning regimen" in the PubMed database, and of the terms "drug interaction", "stem cell transplantation", and "transplantation conditioning" in the Embase database. Only results directly related to the objective of the review were selected. Studies in humans published between January 2000 and November 2020, written in English or Spanish, were prioritized.

Results: The review identified two groups of studies: epidemiological studies and studies analyzing interactions between specific drugs. The 10 epidemiological studies selected, which showed a prevalence of interactions between 60 and 100%, mainly used the Micromedex® database, focused on pharmacokinetic interactions involving azole antifungals.

Resumen

Objetivo: El objetivo principal de este trabajo es identificar, mediante revisión bibliográfica sistemática, los estudios sobre interacciones farmacológicas en pacientes sometidos a trasplante de progenitores hematopoyéticos. Los objetivos secundarios son describir la prevalencia de dichas interacciones y extraer información de interacciones fármaco-fármaco concretas.

Método: Búsquedas en PubMed con los términos "drug-drug interaction", "drug interaction", "stem cell transplant", "transplantation conditioning" y "conditioning regimen" y en Embase "drug interaction", "stem cell transplantation" y "transplantation conditioning", seleccionando aquellos resultados relacionados directamente con el objetivo de la revisión. Se priorizaron estudios en humanos, en idiomas inglés y español, entre enero de 2000 y noviembre de 2020.

Resultados: La revisión identificó dos grupos de estudios (epidemiológicos y de análisis de interacciones entre fármacos concretos). Los 10 estudios epidemiológicos mostraron una prevalencia de interacciones entre el 60% y el 100%, la base de datos más utilizada fue Micromedex®, el mecanismo farmacocinético y los fármacos más implicados fueron los antifúngicos azólicos, con resultados muy heterogéneos. Los 52 estudios de interacciones entre

KEYWORDS

Drug interactions; Drug-drug interactions;
Hematopoietic stem cell transplantation; Conditioning regimen;
Transplantation conditioning; Early post-transplant stage;
Bone marrow transplantation; Systematic review.

PALABRAS CLAVE

Interacción farmacológica; Interacción fármaco-fármaco;
Trasplante de progenitores hematopoyéticos;
Régimen acondicionamiento; Acondicionamiento pretrasplante;
Etapa temprana postrasplante; Trasplante médula ósea;
Revisión sistemática.



Los artículos publicados en esta revista se distribuyen con la licencia
Articles published in this journal are licensed with a
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
<http://creativecommons.org/licenses/by-nc-sa/4.0/>
La revista Farmacia no cobra tasas por el envío de trabajos,
ni tampoco por la publicación de sus artículos.

Results were highly heterogeneous. Of the 52 drug interaction studies reviewed, the majority were pharmacokinetic and focused primarily on the interactions of azole antifungals with calcineurin inhibitors. Some studies described the possible relationship between the interactions and specific adverse reactions or deaths from adverse events.

Conclusions: The prevalence of drug-drug interactions in patients undergoing hematopoietic stem cell transplantation is high, with heterogeneous results both in terms of prevalence and of the profile of the interactions resulting from the use of disparate study designs and databases. The most common factor associated with drug-drug interactions was the number of drugs administered. Studies evaluating drug-drug interactions are mostly pharmacokinetic and focus mainly on azole antifungals and calcineurin inhibitors. It would be important to unify the criteria followed in epidemiological studies to obtain results that may help establish risk reduction strategies and conduct a more in-depth investigation into the pharmacodynamic mechanisms involved and into the interactions between other drugs frequently used in patients undergoing transplantation, including those recently introduced in our therapeutic arsenal.

Introduction

The purpose of hematopoietic stem cell transplantation (HSCT) in the context of malignant diseases is to regenerate bone marrow function, often compromised by prior conditioning regimens, and/or to trigger a graft versus tumor effect^{1,2}. Conditioning regimens may result in significant complications³, which tend to increase the patients' drug intake and the potential for drug-drug interactions (DDIs). The most worrisome DDIs are those that have a negative effect on the patient. As such, these DDIs must be identified, prevented and resolved^{4,5}.

Patients undergoing HSCT are usually treated with complex pharmacological regimens, which may lead to multiple DDIs, increasing the risk of adverse events or reducing therapeutic effectiveness. In fact, several authors have reported severe adverse events such as rhabdomyolysis^{6,7} and even life-threatening complications in the context of HSCT⁸. Other factors that may contribute to increasing the risk of DDIs include the number of drugs administered, the length of hospital stay and the type of procedure performed. Moreover, these patients present with associated comorbidities including renal and hepatic dysfunction, an impaired nutritional status and protein-binding displacement, which increases the risk of clinically significant DDIs⁹⁻¹¹.

The main purpose of this article was to carry out a systematic literature review to identify studies on DDIs occurring in patients undergoing HSCT. Secondary goals included a description of the prevalence of such DDIs and the collection of data on specific DDIs.

Methods

A structured literature review was carried out using PubMed and Embase. The goal was to identify as many original articles as possible dealing with DDIs in patients undergoing HSCT following the PRISMA methodology. The analysis included clinical trials, observational studies, case reports or original case series, and letters to the editor. To be included, studies had to report results directly associated with the purpose of the review, they had to have been written in either English or Spanish, and their publication date had to be comprised between 1 January 2000 and 27 November 2020. Publications not related to DDIs and those related to DDIs but not to HSCT, as well as articles published only as oral papers for submission to a conference, were excluded from the analysis.


Search terms for *all fields* were: *drug-drug interaction*, *drug interaction*, *stem cell transplant*, *transplantation conditioning* and *conditioning regimen* for PubMed; and *drug interaction*, *stem cell transplantation* and *transplantation conditioning* for Embase, combined with Boolean operators *or* and *and*. Additional publications cited in the selected articles were also included in the search given their significance in the authors' opinion. Figure 1 shows the process followed to select the articles included in the search.

The most relevant data in each publication was extracted by one of the authors and independently checked by another author. Any discrepancies were resolved by a third investigator. The selected publications were then

fármacos fueron casi todos farmacocinéticos y se centraron fundamentalmente en las interacciones de antifúngicos azólicos e inhibidores de la calcineurina. Algunos estudios describieron la posible relación entre interacciones y reacciones adversas concretas o muertes por efectos adversos.

Conclusiones: La prevalencia de interacciones en pacientes sometidos a trasplante de progenitores hematopoyéticos es elevada, siendo los resultados heterogéneos, tanto en prevalencia como en el perfil de las interacciones. En ello repercuten las diferencias en los diseños de los estudios y en las bases de datos utilizadas. Entre los factores relacionados con el riesgo de que se produzcan interacciones farmacológicas destaca el elevado número de fármacos administrados. Los estudios que evalúan las interacciones fármaco-fármaco son casi todos farmacocinéticos y se centran mayoritariamente en antifúngicos azólicos e inhibidores de la calcineurina. Sería importante unificar los criterios de los estudios epidemiológicos para obtener resultados que ayuden a establecer estrategias de reducción de riesgo, investigar en mayor profundidad las interacciones de mecanismo farmacodinámico, las interacciones entre otros fármacos de uso frecuente en el trasplante y en aquellos de introducción reciente en el arsenal terapéutico.

Figure 1. Article selection process.



run through an initial filter where the title, abstract and main text of the articles were screened to ensure that they were in line with the purpose of the present study. When the same information was repeated, the most up-to-date, clear and comprehensive study was selected.

The epidemiological features of all the studies were duly analyzed and recorded. Such features included: study type; database used; rate and prevalence of DDIs; overall number of DDIs; number of DDIs per patient; most usual DDIs; mechanism of action; severity; risk factors; and most commonly involved drugs; as well as the DDI effect observed in drug-to-drug studies.

Results

The literature search resulted in 2,715 records (1,187 for PubMed and 1,528 for Embase). After removal of duplications, of articles whose title or abstract were unrelated to the purpose of this study, and of publications sum-

marizing conference presentations, a total of 62 records were obtained that met the inclusion criteria. Ten of these were classified as epidemiological studies and 52 as studies analyzing the effects of DDIs. Tables 1 and 2 show the characteristics, objectives and main findings of the studies included.

Table 1. Summary of the epidemiological studies included in the review.

Reference	Type of study	Number of patients	Database used	Objective	Findings/main results
Valverde <i>et al.</i> 2018 ⁹	Retrospective observational cohort study, Brazil	53	Micromedex®	Prevalence of DDI between anti-infectious, antineoplastic, and immunomodulating agents during conditioning.	Prevalence: 69.8%. 97.3% exhibited symptoms potentially associated with DDI. Most severe DDI: cyclophosphamide-cyclosporine.
Hadjibabaie <i>et al.</i> 2013 ¹²	Cross-sectional study, Iran	83	Lexi-Interact On-Desktop software®	DDI frequency and profile. DDI risk factors.	Prevalence: 62.88%. 185 DDIs. Pharmacokinetic DDIs: 69.73%. Most common DDI: cotrimoxazole-fluconazole (27.27%). DDI risk factor: number of drugs.
Fernández de Palencia <i>et al.</i> 2017 ¹³	Prospective observational descriptive study, Spain	58	Micromedex® & Drug-Interaction Facts®	Prevalence of clinically relevant DDIs, most frequent DDIs and DDI risk factors in patients admitted to the hematology department.	Prevalence: 74.1% (Micromedex®) and 56.8% (Drug-Interaction Facts®). 2061 DDIs in 317 treatments of 58 patients (73 treatments of 10 patients were HSCT). Most commonly involved drugs: azole antifungals, immunosuppressants, antiemetics, antacids, antidepressants, and corticosteroids. DDI risk factor: number of non-antineoplastic drugs.
Gholaminezhad <i>et al.</i> 2014 ¹⁴	Retrospective observational study, Iran	384	Lexi-Interact On-Desktop	Patterns and risk factors associated to potentially moderate or severe DDIs before and immediately after HSCT.	DDI prevalence: 100%. 13,600 DDIs. Median DDI/patient: 41. 100% patients ≥ 1 DDI, 81.8% DDIs were moderate and 54.3% pharmacokinetic. Most common DDI: cotrimoxazole-fluconazole (95.3%). 61.5% DDIs caused by HSCT-related medication. DDI risk factors: type of HSCT and number of drugs administered.
Egger <i>et al.</i> 2010 ¹⁵	Retrospective observational study, Switzerland	36	Drug-Reax®	Prevalence and frequency of potential antifungal-related DDIs.	Prevalence: 86.11%. 57 DDIs in 31 patients. Most common DDI: voriconazole-cyclosporine (20 patients).
Guastaldi & Secoli. 2011 ¹⁶	Prospective cross-sectional study, Brazil	70	Drug Interactions Facts® & Drug Interactions Handbook®	Prevalence of potential antimicrobial-related DDIs (frequency and severity). Factors associated with DDIs.	Prevalence: 71.4%. 13 DDIs in 50% of patients (fluconazole 53.8%, ciprofloxacin 30.8% and cotrimoxazole 15.4%). Moderate DDIs: 92.3%, late-onset DDIs: 61.5%, and DDIs requiring treatment monitoring: 76.9%. Factors associated with DDI risk: ≥ 4 drugs, age 40-49, and male sex.
Jaklic <i>et al.</i> 2013 ¹⁷	Retrospective observational study, United States	84	University of Washington Drug Interaction Database, Stockley's Drug Interactions, Lexicomp™, Micromedex®, Drugs.com	Prevalence of mycophenolic acid-related DDIs within the first 21 days post-HSCT.	Prevalence: 87%. 135 DDIs. 87% patients ≥ 1 DDI. 5.9% of drugs ≥ 1 DDI. Median DDIs/patient 2 (0-4). 10 DDIs ↓ AUC and 1 DDI ↑ AUC of mycophenolic acid. Most common DDIs involved: cyclosporine (n = 58), omeprazole (n = 28) and pantoprazole (n = 20). Most DDIs were related with HSCT-specific medication.
Sánchez <i>et al.</i> 2019 ¹⁸	Retrospective observational study, France	31	Therisque®	Prevalence and density of DDIs and evolution of renal function.	Prevalence: 25.6%. 795 DDIs (66 pharmacokinetic and 729 pharmacodynamic). Contraindicated DDIs: rare and pharmacokinetic. Mean number of DDIs associated with nephrotoxicity/patient: 7. Mean number of DDI days associated with nephrotoxicity/patient: 77. ↓ GFR was correlated with the number of days with potentially nephrotoxic DDIs.
Guastaldi <i>et al.</i> 2011 ¹⁹	Cross-sectional study, Brazil	70	Drug-Reax®	Prevalence of potential DDIs during the pre-infusion period (day -1) and description of DDIs (frequency and severity).	Prevalence: 60.0%. 128 DDIs (85.9% of moderate severity, 52.3% pharmacokinetic, 82.8% late-onset). 60% patients ≥ 1 DDIs, 21.4% patients ≥ 1 severe DDIs. Most common severe DDIs: fluconazole-cotrimoxazole, diazepam-fentanyl, fluconazole-levofloxacin, and fluconazole-fentanyl.
Trevisan <i>et al.</i> 2015 ²⁰	Cross-sectional study, Brazil	40	Drug-Reax®	Prevalence of DDI on the day the hematopoietic stem cells were infused (day 0).	DDI prevalence: 82.5%. 80.9% DDI were severe and 61.9% of undetermined onset. 52.4% DDIs based on good or excellent scientific evidence.

AUC: area under the curve; DDI: drug-drug interaction; GFR: glomerular filtration rate; HSCT: hematopoietic stem cell transplant.

Table 2. Summary of the pharmacokinetic studies included in the review

Reference	Type of study	Number of patients	Main findings
Cool & Gulbis 2013 ⁶	Case report, United States	1	The patient developed rhabdomyolysis which was suspected to have been caused by a DDI between simvastatin and voriconazole.
Vives <i>et al.</i> 2008 ⁷	Letter to the editor (case report), Spain	1	Concomitant use of simvastatin, cyclosporine A and risperidone resulted in rhabdomyolysis and renal failure.
Yang <i>et al.</i> 2013 ⁸	Retrospective observational study, China	104	Itraconazole and voriconazole lead to increased concentrations of cyclosporine A.
Leather <i>et al.</i> 2006 ²¹	Prospective observational study, United States	17	Itraconazole leads to increased concentrations of tacrolimus and cyclosporine A. No correlation was found between the concentration of itraconazole and that of tacrolimus or cyclosporine A. 50-100% tacrolimus and cyclosporine A dose reductions are required when itraconazole is introduced in the treatment regimen.
Kawazoe <i>et al.</i> 2006 ²²	Retrospective case series, Japan	3	Serum concentrations of tacrolimus increased 4.5 times after a change from fluconazole to voriconazole. This required a 20% tacrolimus dose reduction.
Mihara <i>et al.</i> 2008 ²³	Retrospective observational study, Japan	53	The change from intravenous to oral fluconazole significantly increased the serum levels of cyclosporine A and tacrolimus.
Mori <i>et al.</i> 2009 ²⁴	Retrospective observational study, Japan	10	Orally administered itraconazole leads to increased concentrations of calcineurin inhibitors. The observed increase in itraconazole serum levels was significantly correlated with an increase in calcineurin inhibitor concentrations.
Nara <i>et al.</i> 2010 ²⁵	Letter to the editor (case report), Japan	1	Itraconazole inhibits the tacrolimus metabolism via the CYP3A4 enzyme.
Mori <i>et al.</i> 2012 ²⁶	Retrospective observational study, Japan	25	Concentrations of tacrolimus increased significantly when administered with oral voriconazole. Serum concentrations of voriconazole were not correlated with higher concentrations of tacrolimus.
Kikuchi <i>et al.</i> 2012 ²⁷	Retrospective observational study, Japan	20	DDIs were observed between voriconazole and cyclosporine. Voriconazole led to a significant increase in cyclosporine when both drugs were administered concomitantly. Voriconazole serum levels were not significantly correlated with an increase in cyclosporine concentrations.
Nara <i>et al.</i> 2013 ²⁸	Prospective observational study, Japan	16	Itraconazole led to increased concentrations of cyclosporine A and tacrolimus. DDIs between oral tacrolimus and itraconazole were significantly more severe than between oral cyclosporine and itraconazole.
Iwamoto <i>et al.</i> 2015 ²⁹	Prospective cohort study, Japan	21	Voriconazole leads to significantly higher concentrations of tacrolimus. Differences observed in the serum concentrations of intravenous tacrolimus could be attributable to genetic variations in CYP3A5. The magnitude of hepatic interactions between tacrolimus and voriconazole is impacted by the CYP3A5 & CYP2C19 gene polymorphism.
El-Asmar <i>et al.</i> 2015 ³⁰	Case report, United States	1	Topically applied cotrimoxazole leads to increased serum levels of sirolimus and tacrolimus.
Masoumi <i>et al.</i> 2017 ³¹	Prospective cohort study, Iran	29	Cyclosporine concentrations increased in a statistically significant way following the start of (both oral and intravenous) voriconazole therapy. A significant correlation was found between voriconazole concentrations and the increase in cyclosporine plasma levels.
Valenzuela <i>et al.</i> 2017 ³²	Retrospective observational study, Chile	7	Voriconazole leads to increased serum concentrations of cyclosporine A.
Kieu <i>et al.</i> 2018 ³³	Retrospective observational study, United States	30	Isavuconazole leads to a moderate increase in tacrolimus and sirolimus serum concentrations.
Collins <i>et al.</i> 2019 ³⁴	Retrospective observational study, United States	79	Patients where no empirical posaconazole dose reduction was applied took longer ($p < 0.05$) to achieve therapeutic concentrations of tacrolimus. Their rate of subtherapeutic posaconazole levels was higher ($p < 0.001$) than in patients where an empirical dose reduction was applied.
Mimura <i>et al.</i> 2019 ³⁵	Retrospective observational study, Japan	52	Voriconazole lead to greater increases in tacrolimus serum levels than fluconazole following a change from intravenous to extended-release oral tacrolimus.
Utano <i>et al.</i> 2020 ³⁶	Retrospective observational study, Japan	38	Patients on voriconazole exhibited higher tacrolimus serum concentrations, regardless of the route of administration employed, although the increase was greater when tacrolimus was administered orally.
Marty <i>et al.</i> 2006 ³⁷	Case series, United States	11	Voriconazole and sirolimus may be safely co-administered if a 90% empirical dose reduction of sirolimus is implemented.
Said <i>et al.</i> 2006 ³⁸	Case report, United States	1	Itraconazole led to increased concentrations of sirolimus. This DDI could be regarded as the cause of the patient's death (disseminated adenovirus infection that resulted in terminal multi-organ failure).

Table 2 (cont.). Summary of the pharmacokinetic studies included in the review

Reference	Type of study	Number of patients	Main findings
Kubiak <i>et al.</i> 2012 ³⁹	Case series, United States	15	Concomitant use of posaconazole and sirolimus is safe if a 33-50% empirical dose reduction of sirolimus is implemented.
Ceberio <i>et al.</i> 2015 ⁴⁰	Retrospective observational study, United States	67	Concomitant administration of sirolimus and voriconazole is safe and well-tolerated if a 90% empirical dose reduction of sirolimus is implemented.
Greco <i>et al.</i> 2016 ⁴¹	Retrospective observational study, Italy	49	A 55-70% reduction in the daily dose of sirolimus in 19 of these patients was implemented following introduction of posaconazole. Despite the dose reduction, 1/3 of patients exhibited an increase in sirolimus serum levels during the first week of co-administration.
Nwaroh <i>et al.</i> 2018 ⁴²	Case series, Canada	3	Discontinuation of fluconazole resulted in a marked reduction of trough plasma levels of sirolimus. Patients required a > 200% dose increase to reach therapeutic levels.
Marr <i>et al.</i> 2004 ⁴³	Comparative randomized trial, United States	105	Patients on fluconazole were more exposed to cyclophosphamide and dechloroethyl-cyclophosphamide, while those on itraconazole were more exposed to 4-hydroxy-cyclophosphamide and 4-keto-cyclophosphamide, which are more toxic metabolites.
Miura <i>et al.</i> 2011 ⁴⁴	Case report, Japan	1	S-warfarin concentrations increased 7.3 times when the drug was administered concomitantly with oral itraconazole.
Fakih <i>et al.</i> 2012 ⁴⁵	Letter to the editor (case series), United States	5	Systemic concentrations of budesonide may increase in the drug is administered concomitantly with an azole.
Yasu <i>et al.</i> 2016 ⁴⁶	Retrospective observational study, Japan	59	Trough levels of voriconazole were significantly higher in patients on concomitant treatment with lansoprazole as compared with rabeprazole.
Furrer <i>et al.</i> 2002 ⁴⁷	Retrospective observational comparative study, Switzerland	84	Concomitant administration of amphotericin B and cyclosporine leads to a statistically significant but clinically tolerable renal function impairment.
Nagamura <i>et al.</i> 2003 ⁴⁸	Retrospective observational study, Japan	103	Cyclophosphamide may reduce cyclosporine A serum concentrations for at least two weeks following conditioning.
Ibrahim <i>et al.</i> 2008 ⁴⁹	Retrospective observational study, United States	26	Aprepitant led to statistically higher serum concentrations of tacrolimus when both drugs were administered concomitantly. This increase had no clinical repercussions thanks to pharmacokinetic monitoring.
Shayani <i>et al.</i> 2012 ⁵⁰	Case series, United States	85	The combination of sirolimus and aprepitant leads to a dual increase in sirolimus serum levels as both agents are CYP3A4 substrates. This is not observed with the tacrolimus- aprepitant combination.
Fukuoka <i>et al.</i> 2010 ⁵¹	Observational study, Japan	6	The fact that tacrolimus concentrations remained stable with and without concomitant treatment with micafungin led to the conclusion that there was no DDI between both agents.
Inoue <i>et al.</i> 2012 ⁵²	Prospective comparative study, Japan	15	A 150 mg daily dose of micafungin is safe and does not result in significantly interactions with cyclosporine.
Nishimoto <i>et al.</i> 2017 ⁵³	Retrospective observational study, Japan	50	Concentrations of cyclosporine increased significantly when the drug was administered together with caspofungin. Tacrolimus concentrations, however, exhibited no differences.
Miceli <i>et al.</i> 2012 ⁵⁴	Letter to the editor (case report), United States	1	Ritonavir leads to increased serum concentrations of tacrolimus when both drugs are administered concomitantly.
Bernard <i>et al.</i> 2014 ⁵⁵	Retrospective observational study, France	51	Trough cyclosporine A serum levels increased significantly in patients treated with nifedipine and amlodipine, while they remained stable in patients treated with lacidipine.
Bleyzac <i>et al.</i> 2014 ⁵⁶	Case series, France	6	Cyclosporine concentrations increased significantly following a 3-7 day course of imatinib.
Atiq <i>et al.</i> 2016 ⁵⁷	Retrospective observational study, the Netherlands	16	Concomitant administration of cyclosporine and imatinib led to a significant increase of the former's serum concentrations in all patients. A serum concentration-based dose adjustment led to a 27% reduction in the cyclosporine dose administered.
Kitazawa <i>et al.</i> 2017 ⁵⁸	Retrospective observational study, Japan	6	Fentanyl decreased tacrolimus clearance when both agents were administered together. It is proposed that a 40% tacrolimus dose reduction should be implemented when the drug is used in combination with fentanyl.
Guo <i>et al.</i> 2019 ⁵⁹	Case series, Japan	3	Letermovir inhibits CYP3A4 and leads to 1.5-to-2-fold increases in the concentration of tacrolimus, regardless of the route of administration used.
Maples <i>et al.</i> 2020 ⁶⁰	Letter to the editor, United States	1	Letermovir can be used safely in combination with tacrolimus or cyclosporine. Dose adjustments of calcineurin inhibitors are not recommended prior to administration of letermovir.

Table 2 (cont.). Summary of the pharmacokinetic studies included in the review

Reference	Type of study	Number of patients	Main findings
Mancini <i>et al.</i> 2020 ⁶¹	Case report, United States	1	Cyclosporine serum levels increased by 70% following administration of midostaurin. The cyclosporine dose was reduced by 40% to achieve therapeutic levels.
Nilsson <i>et al.</i> 2003 ⁶²	Retrospective observational comparative study, Sweden	24	Metronidazole leads to a significant increase in busulfan serum levels. Concomitant use of both drugs must be avoided.
Chung <i>et al.</i> 2017 ⁶³	Case report, South Korea	1	Metronidazole leads to a 57% reduction in busulfan clearance when both agents are administered together.
Sjoo <i>et al.</i> 2003 ⁶⁴	Retrospective observational study, Switzerland	10	N-acetylcysteine is safe and does not alter busulfan's myeloablative effect.
de Castro <i>et al.</i> 2013 ⁶⁵	Retrospective observational study, Brazil	26	Patients treated with fludarabine should receive 30% lower doses of busulfan that if they were not on fludarabine.
Sweiss <i>et al.</i> 2019 ⁶⁶	Case report, United States	1	The increase in cytokine levels observed during treatment with blinatumomab could lead to CYP3A4 suppression and an ensuing metabolism of busulfan, which may reduce its clearing ability.
Bubalo <i>et al.</i> 2012 ⁶⁷	Randomized double-blind placebo-controlled study, United States	1	Aprepitant is well absorbed, does not induce its own metabolism and does not produce DDIs with cyclophosphamide or its metabolites.
Wasko <i>et al.</i> 2017 ⁶⁸	Case report, United States	1	Rifampicin reduces sirolimus serum concentrations.
Engle & Fair 2017 ⁶⁹	Case report, United States	1	Mirabegron increases serum concentrations of sirolimus.

DDI: drug-to-drug interaction.

Eight of the 10 epidemiological studies centered exclusively on patients undergoing HSCT, while the other two included hematological patients in general^{12,13}. The study with the largest patient cohort had 384 subjects¹⁴. Six studies analyzed the DDIs resulting from all the drugs administered, while two studies were dedicated to DDIs associated with the use of antimicrobials^{5,16}, one of them focusing on DDIs associated with anti-infectious, antineoplastic and immunomodulating drugs⁹, and the other on DDIs associated to mycophenolic acid¹⁷. Sánchez *et al.* conducted a separate study of DDIs with the potential to affect renal function, and associated them with a slower glomerular filtration rate¹⁸.

Most studies made specific mention of the database used, the prevalence of DDI, the drugs most commonly involved in DDIs, and the drug combinations most prone to DDIs, including those usually leading to the more severe forms of DDI. The most commonly used database was Micromedex^{9,13,15,17}. The study resulting in the highest number of overall DDIs was Gholaminezhad *et al.*¹⁴ with 13,600 DDIs in 384 patients, whereas the one detecting the lowest amount of DDIs was Guastaldi & Secoli¹⁶ with 13 DDIs in 35 patients.

The perpatient prevalence of DDIs ranged between the 60% reported by Guastaldi *et al.*¹⁹, who used the Drug Reax database[®] and the 100% found by Gholaminezhad *et al.*¹⁴, who used Lexi-Interact[®]. Using a different methodology, and in a hematologic cohort including more patients than just those undergoing HSCT, Fernández de Palencia *et al.*¹³ described a DDI prevalence per drug prescribed of 56.8% using the Drug Interaction Facts database[®] and of 74.1% using the Micromedex database[®].

The mechanism of action of DDIs was mostly pharmacokinetic^{12,14,19}. Interactions were mostly late-onset^{16,19} and the damage was mostly moderate^{4,16,19} or severe²⁰. However, Sánchez *et al.* reported a lower incidence of pharmacokinetic than of pharmacodynamic DDIs¹⁸. Azole antifungals were among the drugs most commonly involved in DDIs in six of the 10 epidemiologic studies analyzed^{12,16,19}.

According to Guastaldi & Secoli¹⁶, factors associated with the risk of developing DDIs included the number of drugs used^{12,14,16}, the prescription of concomitant non-antineoplastic medication^{13,17}, advanced age, and male sex.

Of the 52 studies analyzing the effect of DDIs, most of them pharmacokinetic, 18 focused on DDIs between azole antifungals and calcineurin inhibitors^{7,8,21,36}; six on DDIs between azole antifungals and sirolimus^{37,42};

five on DDIs between azole antifungals and other drugs (cyclophosphamide⁴³, warfarin⁴⁴, budesonide⁴⁵, simvastatin⁶, and proton pump inhibitors⁴⁶); 15 on DDIs between calcineurin inhibitors and other drugs (amphotericin B⁴⁷, cyclophosphamide⁴⁸, aprepitant^{49,50}, micafungin^{51,52}, caspofungin⁵³, ritonavir⁵⁴, calcium channel blockers⁵⁵, imatinib^{56,57}, fentanyl⁵⁸, letermovir^{59,60}, midostaurin⁶¹); five on DDIs between busulfan and other drugs (metronidazole^{62,63}, N-acetylcysteine⁶⁴, fludarabine⁶⁵, blinatumomab⁶⁶); one on DDIs between aprepitant and cyclophosphamide⁶⁷; one on DDIs between rifampicin, sirolimus and voriconazole⁶⁸; and one on DDIs between sirolimus and mirabegron⁶⁹. The main effects of these DDIs are shown in table 2.

According to Yang *et al.*⁸, 10 patients experienced life-threatening complications potentially associated with DDIs between cyclosporine A and itraconazole or voriconazole on administration of supratherapeutic levels of cyclosporine. Six patients developed grade I to III graft-versus-host disease (GVHD) and eventually died from idiopathic pneumonia syndrome or alveolar hemorrhage. Another four patients died from neurological complications associated with cyclosporine A. Other authors have described serious adverse events such as rhabdomyolysis resulting from the interaction of azoles with statins^{6,7}.

Discussion

The present study was based on a compilation of studies reporting on the DDIs suffered by patients undergoing HSCT over the last 20 years. Two groups of studies can be distinguished: epidemiological studies on the one hand, and studies analyzing DDIs between two specific drugs or drug families on the other.

Epidemiological studies on the DDIs suffered by patients undergoing HSCT are scarce and tend to use dissimilar methodologies which lead to highly heterogeneous results. What can be concluded about them is that these studies show a high prevalence of DDIs, particularly potentially severe ones or between contraindicated medications. In addition, results tend to be rather heterogeneous on account, among other reasons, of the use of different databases.

Such heterogeneity can be easily seen in the literature^{20,71}, where significant differences have been found in one same population when the data is analyzed using different databases. For example, Fernandez de Palencia *et al.*

al.¹³ observed different prevalence rates in hematologic patients depending on whether they used the Lexi Interaction Facts® database (56.8%) or the Micromedex® database (74.1%). These differences were greater in the case of oncologic patients⁷² (80% using Micromedex® and 30% using Interaction Facts®) and smaller in pediatric hemato-oncologic patients⁷³ (44.7% using Micromedex® and 51.3% using Drug Interaction Facts®). A statistical analysis of the concordances between the two databases, which compared the DDIs detected across 1,166 treatments, showed that concordance was weak in terms of the capacity to detect potential DDIs and nonexistent for the level of severity and scientific evidence attributed by each database to the same DDI⁷¹. This heterogeneity precludes the use of databases as decision-making tools in clinical practice.

Although epidemiological studies tend to focus on DDIs occurring between drugs that are commonly used in the context of HSCT and whose risk profile is well known, such as calcineurin inhibitors and azoles, other relevant yet somewhat less well-known DDIs such as those associated to CNS depressants (benzodiazepines, morphine derivatives, etc.), antiemetics, corticosteroids, proton pump inhibitors, antidepressants or antibiotics are also reported, albeit in other scenarios^{74,76}.

Other studies, dealing mostly with DDIs between two agents, usually focus on pharmacokinetic mechanisms of action, with none of them to the best of our knowledge analyzing pharmacodynamic DDIs. All pharmacokinetic studies exhibit a similar data collection pattern.

Most published articles describe DDIs between azole antifungals and calcineurin inhibitors, which result in increased serum concentrations of the calcineurin inhibitors caused by an inhibition of the CYP3A4 metabolism. However, the intensity of DDIs tends to depend on the specific antifungal or calcineurin inhibitor used. For example, the increase in calcineurin inhibitor serum concentrations is apparently greater with voriconazole than with fluconazole^{22,35}, whereas the intensity of DDIs involving itraconazole is significantly higher with tacrolimus than with cyclosporine²⁸. Several studies have shown the level of azole concentration not to be associated with an increase in calcineurin inhibitor concentrations^{26,27}. Masoumi *et al.*, however, did find a correlation in that respect³¹. The route of administration also seems to play an important role. Indeed, fluconazole tends to result in more significant DDIs with intravenously administered calcineurin inhibitors when it is administered orally rather than intravenously²³. In the same vein, orally administered tacrolimus is more affected by concomitant use of voriconazole³⁶. It must be pointed out that one of the studies analyzed claims that a DDI between cyclosporine and voriconazole or itraconazole was potentially responsible for the death of 10 patients who experienced subtherapeutic levels of cyclosporine. Six of them died as a result of an idiopathic pneumonia syndrome or an alveolar hemorrhage following the occurrence of GVHD and four as a result of neurologic complications associated to cyclosporine A⁸.

Azole antifungals are usually implicated in a different class of DDI when used together with sirolimus^{37,42}. This combination leads to increased serum concentrations of sirolimus, requiring an empiric dose reduction before it can be combined with azoles. Antifungals may also interact with agents like cyclophosphamide, with fluconazole being safer than itraconazole as the former inhibits CYP2C9, which leads to lower levels of 4-hydroxycyclophosphamide, a toxic cyclophosphamide metabolite⁴³. Azoles can also increase serum concentrations of warfarin⁴⁴, budesonide⁴⁵, simvastatin⁶, and lansoprazole⁴⁶.

Calcineurin inhibitors, for their part, are involved in a significant number of DDIs with agents other than azoles. Tacrolimus and cyclosporine concentrations do not seem to be influenced by the presence of micafungin^{51,52}, and although caspofungin does not seem to have an influence on tacrolimus

concentration levels, but it does seem to increase serum concentrations of cyclosporine⁵³. When combined with amphotericin B, cyclosporine leads to a statistically significant worsening of renal function, which may be clinically controlled if the drug is infused over a 24-hour period and if strict salt replenishment is observed⁴⁷. Cyclosporine has also been found to be involved in DDIs with cyclophosphamide, leading to a decrease in the latter's serum concentrations⁴⁸.

There is generalized concurrence in the literature regarding the effects of DDIs occurring between calcineurin inhibitors and other drugs such as imatinib, which leads to increased cyclosporine concentrations^{56,57}. Nonetheless, in a study of 85 patients, Shayani *et al.*⁵⁰ concluded that aprepitant increases sirolimus but not tacrolimus serum concentrations. Conversely, a study of 26 patients by Ibrahim *et al.*⁴⁹ found that aprepitant did increase tacrolimus serum concentrations. Another example is provided by a study of 46 patients by Maples *et al.*⁶⁰, who claimed that it is not necessary to adjust the dose of calcineurin inhibitors prior to administration of letermovir. However, a 3-case series published by Guo *et al.*⁵⁹ showed that letermovir inhibits CYP3A4 and increases tacrolimus concentrations, which according to these authors warrants a dose reduction.

Some studies have shown that agents belonging to the same therapeutic group can have different DDI profiles. In this respect, Bernard *et al.*⁵⁵ found that nicardipine and amlodipine increase serum concentrations of cyclosporine, while lacidipine had no effect of such concentrations. Finally, two studies showed that concomitant administration of metronidazole⁶² and fludarabine⁶⁵ with busulfan increases the latter's serum concentrations.

In 2008, Vives *et al.* published a series of case reports that brought to light a series of severe adverse events associated with some DDIs. The authors reported that concomitant use of simvastatin, cyclosporine A and risperidone can result in rhabdomyolysis and renal failure⁷. Moreover, in a study describing significant DDIs resulting from recently introduced agents, Mancini *et al.* reported a 70% increase in the serum levels of cyclosporine A when used together with midostaurin⁶¹.

The main limitation of the present study is associated with the heterogeneity of the studies analyzed and the absence of data to quantify the impact of DDIs on patient outcomes.

In summary, all the studies analyzed describe a high prevalence of DDIs in patients undergoing HSCT, with significant disparities across the different authors in terms of the prevalence and characteristics of the DDIs identified. Such disparities are attributable to the way the studies were designed and the databases used. Factors related to the risk of DDIs include the number of drugs concomitantly administered. All studies on DDIs are of a pharmacokinetic nature and focus mainly on DDIs between azole antifungals and calcineurin inhibitors, or between these two drug families and other agents. It would be important to unify the criteria followed by epidemiological studies to produce more consistent outcomes conducive to the implementation of effective risk reduction strategies. It would also be essential to investigate pharmacodynamic DDIs and to carry out a more in-depth analysis of DDIs between other commonly used drugs in the HSCT context and between drugs that have been recently introduced in our therapeutic arsenal.

Funding

No funding.

Conflict of interests

No conflict of interests.

Bibliography

- Adelstein KE, Anderson JG, Taylor AG. Importance of meaning-making for patients undergoing hematopoietic stem cell transplantation. *Oncol Nurs Forum*. 2014;41(2):E172-84. DOI: 10.1188/14.ONF.E172-E184
- Rifón JJ. Trasplante de progenitores hematopoyéticos. En: *An Sist Sanit Navar* [Internet]. 2006 [accessed 04/01/2020]; p. 29. Available at: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137-66272006000400013&lng=en&nrm=iso&tlng=en
- Galgano L, Hutt D. HSCT: How does it work? En: Kenyon M, Babic A, editores. *The European Blood and Marrow Transplantation Textbook for Nurses* [Internet]. Cham: Springer International Publishing; 2018 [accessed 04/01/2020]. p. 23-36. Available at: http://link.springer.com/10.1007/978-3-319-50026-3_2
- Amariles P, Andrés Giraldo N, José Faus M. Interacciones medicamentosas: aproximación para establecer y evaluar su relevancia clínica. *Med Clínica*. 2007;129(1):27-35. DOI: 10.1157/13106681

5. Pejčić A, Janković SM, Opančina V, Babić G, Milosavljević M. Drug–drug interactions in patients receiving hematopoietic stem cell transplantation. *Expert Opin Drug Metab Toxicol.* 2019;15(1):49-59. DOI: 10.1080/17425255.2019.1552256
6. Cool RM, Gulbis AM. Rhabdomyolysis after concomitant use of simvastatin and voriconazole in an allogeneic stem cell transplant patient. *J Pharm Technol [Internet].* 2013 [accessed 02/01/2020]. Available at: <https://journals.sagepub.com/doi/10.1177/875512251302900306>
7. Vives S, Batlle M, Montané E, Ribera JM. Rbdomiólisis e insuficiencia renal aguda secundaria a la interacción de simvastatina, ciclosporina A y risperidona en un paciente receptor de un trasplante alogénico de progenitores hematopoyéticos. *Med Clínica.* 2008;131(17):676. DOI: 10.1157/13128732
8. Yang T, Wu XM, Qiu HQ, Fu DH, Ju JD, Li J, *et al.* Adverse drug interactions as a high-risk factor for lethal posttransplant complications in Chinese population. *Clin Transplant.* 2013;27(2):255-60. DOI: 10.1111/ctr.12070
9. Valverde IA, da Silva MJ, Retto MP. Association between potential drug interactions and clinical outcomes in hematopoietic stem cell transplantations. *J Oncol Pharm Pract.* 2019;25(5):1105-11. DOI: 10.1177/1078155218775195
10. Glotzbecker B, Duncan C, Alyea E, Campbell B, Soiffer R. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. *Biol Blood Marrow Transplant.* 2012;18(7):989-1006. DOI: 10.1016/j.bbmt.2011.11.029
11. Manitspitikul W, McCann E, Lee S, Weir MR. Drug interactions in transplant patients: what everyone should know. *Curr Opin Nephrol Hypertens.* 2009;18(5):404-11. DOI: 10.1097/MNH.0b013e32832edcb2
12. Hadjibabaie M, Badri S, Ataei S, Moslehi AH, Karimzadeh I, Ghavamzadeh A. Potential drug–drug interactions at a referral hematology–oncology ward in Iran: a cross-sectional study. *Cancer Chemother Pharmacol.* 2013;71(6):1619-27. DOI: 10.1007/s00280-013-2162-5
13. Fernández de Palencia Espinosa MÁ, Díaz Carrasco MS, Sánchez Salinas A, de la Rubia Nieto A, Espuny Miró A. Potential drug-drug interactions in hospitalised haematological patients. *J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract.* 2017;23(6):443-53. DOI: 10.1177/1078155216664201
14. Gholaminezhad S, Hadjibabaie M, Gholami K, Javadi MR, Radfar M, Karimzadeh I, *et al.* Pattern and associated factors of potential drug-drug interactions in both pre- and early posthematopoietic stem cell transplantation stages at a referral center in the Middle East. *Ann Hematol.* 2014;93(11):1913-22. DOI: 10.1007/s00277-014-2122-0
15. Egger SS, Meier S, Leu C, Christen S, Gratwohl A, Krähenbühl S, *et al.* Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. *Bone Marrow Transplant.* 2010;45(7):1197-203. DOI: 10.1038/bmt.2009.325
16. Guastaldi RBF, Secoli SR. Drug interactions of anti-microbial agents used in hematopoietic stem cell transplantation. *Rev Lat Am Enfermagem.* 2011;19(4):960-7. DOI: 10.1590/s0104-11692011000400015
17. Jaklić A, Collins CJ, Mrhar A, Sorrow ML, Sandmaier BM, Bemer MJ, *et al.* High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. *Int J Clin Pharmacol Ther.* 2013;51(9):711-7. DOI: 10.5414/CP201884
18. Sánchez L, Bacle A, Lamy T, Le Corre P. Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay. *Cancer Chemother Pharmacol.* 2019;83(5):827-35. DOI: 10.1007/s00280-019-03791-9
19. Guastaldi RBF, Reis AMM, Figueras A, Secoli SR. Prevalence of potential drug–drug interactions in bone marrow transplant patients. *Int J Clin Pharm.* 2011;33(6):1002-9. DOI: 10.1007/s11096-011-9574-2
20. Trevisan DD, Silva JB, Oliveira HC, Secoli SR, Lima MHM. Prevalence and clinical significance of potential drug-drug interaction in hematopoietic stem cell transplantation. *Cancer Chemother Pharmacol.* 2015;75(2):393-400. DOI: 10.1007/s00280-014-2657-8
21. Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. *Biol Blood Marrow Transplant.* 2006;12(3):325-34. DOI: 10.1016/j.bbmt.2005.10.022
22. Kawazoe H, Takiguchi Y, Tanaka H, Fukuoka N, Ohnishi H, Ishida T, *et al.* Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation. *Biol Pharm Bull.* 2006;29(12):2528-31. DOI: 10.1248/bpb.29.2528
23. Mihara A, Mori T, Aisa Y, Yamazaki R, Iketani O, Tanigawara Y, *et al.* Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole. *Eur J Clin Pharmacol.* 2008;64(11):89-91. DOI: 10.1007/s00228-007-0395-0
24. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole. *Int J Hematol.* 2009;90(1):103-7. DOI: 10.1007/s12185-009-0344-z
25. Nara M, Takahashi N, Miura M, Saitoh H, Kagaya H, Sawada K. Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3. *Am J Hematol.* 2010;85(8):634-5. DOI: 10.1002/ajh.21759
26. Mori T, Kato J, Yamane A, Sakurai M, Kohashi S, Kikuchi T, *et al.* Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation. *Int J Hematol.* 2012;95(5):564-9. DOI: 10.1007/s12185-012-1057-2
27. Kikuchi T, Mori T, Yamane A, Kato J, Kohashi S, Okamoto S. Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation. *Clin Transplant.* 2012;26(5):E544-8. DOI: 10.1111/ctr.12016
28. Nara M, Takahashi N, Miura M, Niioka T, Kagaya H, Fujishima N, *et al.* Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants. *Eur J Clin Pharmacol.* 2013;69(6):1321-9. DOI: 10.1007/s00228-013-1471-2
29. Iwamoto T, Monma F, Fujieda A, Nakatani K, Gayle AA, Nobori T, *et al.* Effect of genetic polymorphism of CYP3A5 and CYP2C19 and concomitant use of voriconazole on blood tacrolimus concentration in patients receiving hematopoietic stem cell transplantation. *Ther Drug Monit.* 2015;37(5):581-8. DOI: 10.1097/FTD.0000000000000182
30. El-Asmar J, González R, Bookout R, Mishra A, Kharfan-Dabaja MA. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. *Hematol Oncol Stem Cell Ther.* 2016;9(4):157-61. DOI: 10.1016/j.hemonc.2015.11.001
31. Masoumi HT, Hadjibabaie M, Vaezi M, Ghavamzadeh A. Evaluation of the interaction of intravenous and oral voriconazole with oral cyclosporine in Iranian HSCT patients. *J Res Pharm Pract.* 2017;6(2):77-82. DOI: 10.4103/jrpp.jrpp_16_163
32. Valenzuela R, Torres JP, Salas C, Gajardo I, Palma J, Catalán P, *et al.* Evaluación de interacción medicamentosa de voriconazol-ciclosporina en pacientes pediátricos que reciben trasplante de precursores hematopoyéticos [2013-2014]. *Rev Chil Infectol.* 2017;34(1):14-8. DOI: 10.4067/S0716-10182017000100002
33. Kieu V, Jhangiani K, Dadwal S, Nakamura R, Pon D. Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study. *Transpl Infect Dis.* 2019;21(1):e13007. DOI: 10.1111/tid.13007
34. Collins J, Shea K, Parsad S, Plach K, Lee P. The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation. *J Oncol Pharm Pract [Internet].* 2019 [accessed 02/01/2020]. Available at: <https://journals.sagepub.com/doi/10.1177/1078155219833440>
35. Mimura A, Yamaori S, Ikemura N, Katsuyama Y, Matsuzawa N, Ohmori S. Influence of azole antifungal drugs on blood tacrolimus levels after switching from intravenous tacrolimus to once-daily modified release tacrolimus in patients receiving allogeneic hematopoietic stem cell transplantation. *J Clin Pharm Ther.* 2019;44(4):565-71. DOI: 10.1111/jcpt.12834
36. Utano T, Kato M, Osumi T, Shioda Y, Kiyotani C, Terashima K, *et al.* Tacrolimus blood concentration increase depends on administration route when combined with voriconazole in pediatric stem cell transplant recipients. *Pediatr Transplant.* 2020;24(1):e13619. DOI: 10.1111/petr.13619
37. Marty FM, Lowry CM, Cutler CS, Campbell BJ, Fiumara K, Baden LR, *et al.* Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2006;12(5):552-9. DOI: 10.1016/j.bbmt.2005.12.032
38. Said A, Garnick JJ, Dieterle N, Peres E, Abidi MH, Ibrahim RB. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. *Pharmacother J Hum Pharmacol Drug Ther.* 2006;26(2):289-95. DOI: 10.1592/phco.26.2.289
39. Kubiak DV, Koo S, Hammond SP, Armand P, Baden LR, Antin JH, *et al.* Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants. *Biol Blood Marrow Transplant.* 2012;18(9):1462-5. DOI: 10.1016/j.bbmt.2012.04.015
40. Ceberio I, Dai K, Devlin SM, Barke JN, Castro-Malaspina H, Goldberg JD, *et al.* Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2015;50(3):438-43. DOI: 10.1038/bmt.2014.286
41. Greco R, Barbanti MC, Lupo Stranghellini M, Giglio F, Morelli M, Messina C, *et al.* Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. *Bone Marrow Transplant Lond.* 2016;51(7):1022-4. DOI: 10.1038/bmt.2016.112
42. Nwaroh E, Jupp J, Jadusinh E, Guilcher G. Clinical impact and management of fluconazole discontinuation on sirolimus levels in bone marrow transplant patients. *J Oncol Pharm Pract.* 2018;24(3):235-8. DOI: 10.1177/1078155217701293

43. Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, *et al.* Cyclophosphamide metabolism is affected by azole antifungals. *Blood*. 2004;103(4):1557-9. DOI: 10.1182/blood-2003-072512
44. Miura M, Takahashi N, Kanno S, Kato S, Nara M, Itoh M, *et al.* Drug interaction of (S)-warfarin, and not (R)-warfarin, with itraconazole in a hematopoietic stem cell transplant recipient. *Clin Chim Acta Int J Clin Chem*. 2011;412(21-22):2002-6. DOI: 10.1016/j.cca.2011.06.035
45. El Fakih R, Obi GA, Scholoff A, Carrum G, Kamble RT. Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azoles. *Bone Marrow Transplant*. 2012;47(10):1370-1. DOI: 10.1038/bmt.2012.17
46. Yasu T, Konuma T, Kato S, Kurokawa Y, Takahashi S, Tojo A. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients. *Ann Hematol*. 2016;95(11):1845-51. DOI: 10.1007/s00277-016-2782-z
47. Furrer K, Schaffner A, Vavricka SR, Halter J, Imbof A, Schanz U. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogeneic stem cell transplantation. *Swiss Med Wkly*. 2002;132(23-24):316-20.
48. Nagamura F, Takahashi T, Takeuchi M, Iseki T, Ooi J, Tomonari A, *et al.* Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation. *Bone Marrow Transplant Lond*. 2003;32(11):1051-8. DOI: 10.1038/sj.bmt.1704259
49. Ibrahim RB, Abidi MH, Ayash LJ, Cronin SM, Cadotte C, Mulawa J, *et al.* Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation. *J Oncol Pharm Pract*. 2008;14(3):113-21. DOI: 10.1177/1078155208089846
50. Shayani S, Palmer JM, Stiller T, Chan H, Keuylia S, Parker P, *et al.* Aprepitant (Emond) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT. *Bone Marrow Transplant*. 2012;47(2):291-3. DOI: 10.1038/bmt.2011.42
51. Fukuoka N, Imataki O, Ohnishi H, Kitanaka A, Kubota Y, Ishida T, *et al.* Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. *Transplant Proc*. 2010;42(7):2725-30. DOI: 10.1016/j.transproceed.2010.04.030
52. Inoue Y, Saito T, Ogawa K, Nishio Y, Kosugi S, Suzuki Y, *et al.* Drug interactions between micafungin at high doses and cyclosporine A in febrile neutropenia patients after allogeneic hematopoietic stem cell transplantation. *Int J Clin Pharmacol Ther*. 2012;50(11):831-7. DOI: 10.5414/CP201738
53. Nishimoto M, Koh H, Tokuwame A, Makuuchi Y, Kuno M, Takakuwa T, *et al.* Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation. *Br J Clin Pharmacol*. 2017;83(9):2000-7. DOI: 10.1111/bcp.13303
54. Miceli M, Cronin S, Ayash L, Alangaden G, Chandrasekar PH. Significant interaction of tacrolimus with ritonavir during allogeneic hematopoietic SCT in an HIV-infected patient. *Bone Marrow Transplant*. 2012;47(8):1140-2. DOI: 10.1038/bmt.2011.230
55. Bernard E, Goutelle S, Bertrand Y, Bleyzac N. Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. *Ann Pharmacother*. 2014;48(12):1580-4. DOI: 10.1177/1060028014550644
56. Bleyzac N, Kebaili K, Mialou V, Bertrand Y, Goutelle S. Pharmacokinetic drug interaction between cyclosporine and imatinib in bone marrow transplant children and model-based reappraisal of imatinib drug interaction profile. *Ther Drug Monit*. 2014;36(6):724-9.
57. Atiq F, Broers AEC, Andrews LM, Doorduijn JK, Koch BCP, Van Gelder T, *et al.* A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib. *Eur J Clin Pharmacol*. 2016;72(6):719-23. DOI: 10.1007/s00228-016-2038-9
58. Kitazawa F, Fuchida SI, Kado Y, Ueda K, Kokufu T, Okano A, *et al.* Pharmacokinetic interaction between tacrolimus and fentanyl in patients receiving allogeneic hematopoietic stem cell transplantation. *Ann Transplant*. 2017;22:575-80. DOI: 10.12659/aot.904505
59. Guo Y, Abumiya M, Yamashita T, Ubukawa K, Takahashi N. Pharmacokinetics of tacrolimus coadministered with letermovir in allogeneic hematopoietic stem cell transplantation patients. *Clin Pharmacol Drug Dev*. 2019;8(3):411-2. DOI: 10.1002/cpdd.669
60. Maples KT, Maloy M, Devlin S, Lin A, DeRespiris L, Griffin M, *et al.* Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. *Bone Marrow Transplant [Internet]*. 2020 [accessed 02/01/2020]. Available at: <http://www.nature.com/articles/s41409-020-0785-9>
61. Mancini R, LaMontagne L, Williams T, Kreisle W, Petersen F. Midostaurin and cyclosporine drug interaction: A case report. *J Clin Pharm Ther*. 2020;45(2):384-7. DOI: 10.1111/jcpt.13077
62. Nilsson C, Aschan J, Hentschke P, Ringdén O, Ljungman P, Hassan M. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2003;31(6):429-35. DOI: 10.1038/sj.bmt.1703896
63. Chung H, Yu KS, Hong KT, Choi JY, Hong CR, Kang HJ, *et al.* A significant influence of metronidazole on busulfan pharmacokinetics: a case report of therapeutic drug monitoring. *Ther Drug Monit*. 2017;39(3):208-10. DOI: 10.1097/FTD.0000000000000395
64. Sjöf F, Aschan J, Barkholt L, Hassan Z, Ringdén O, Hassan M. N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2003;32(4):349-54. DOI: 10.1038/sj.bmt.1704143
65. De Castro FA, Lanchote VL, Voltarelli JC, Colturato VAR, Simões BP. Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. *J Clin Pharmacol*. 2013;53(11):1205-11. DOI: 10.1002/jcph.130
66. Sweiss K, Quigley JG, Oh A, Lee J, Ye R, Rondelli D, *et al.* A novel drug interaction between busulfan and blinatumomab. *J Oncol Pharm Pract*. 2019;25(1):226-8. DOI: 10.1177/1078155217729745
67. Bubalo JS, Cherala G, McCune JS, Munar MY, Tse S, Maziarz R. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. *J Clin Pharmacol*. 2012;52(4):586-94. DOI: 10.1177/0091270011398243
68. Wasko JA, Westholder JS, Jacobson PA. Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient. *J Oncol Pharm Pract*. 2017;23(1):75-9. DOI: 10.1177/1078155215624263
69. Engle JA, Fair C. Sirolimus and mirabegron interaction in a hematopoietic cell transplant patient. *J Oncol Pharm Pract [Internet]*. 2017 [accessed 02/01/2020]. Available at: <https://journals.sagepub.com/doi/10.1177/1078155217726161>
70. Vitry AI. Comparative assessment of four drug interaction compendia. *Br J Clin Pharmacol*. 2007;63(6):709-14. DOI: 10.1111/j.1365-2125.2006.02809.x
71. Fernández de Palencia Espinosa MÁ, Espuny Miró A, Díaz Carrasco MS. Consistency among two drug interaction compendia in onco-haematological inpatients. *Eur J Clin Pharm Aten Farm*. 2016;18(2):90-7.
72. Fernández de Palencia Espinosa MÁ, Díaz Carrasco MS, Alonso Romero JL, de la Rubia Nieto A, Espuny Miró A. Potential drug-drug interactions in oncological adult inpatients at a Spanish hospital: epidemiology and risk factors. *Int J Clin Pharm*. 2015;37(6):1021-7. DOI: 10.1007/s11096-015-0195-z
73. Fernández de Palencia Espinosa MA, Díaz Carrasco MS, Fuster Soler JL, Ruiz Merino G, De la Rubia Nieto MA, Espuny Miró A. Pharmacoepidemiological study of drug-drug interactions in onco-hematological pediatric patients. *Int J Clin Pharm*. 2014;36(6):1160-9. DOI: 10.1007/s11096-014-0011-1
74. Díaz-Carrasco MS, Alanchel-Rivadeneira M, Tomás-Luiz A, Pelegrín-Montesinos S, Ramírez-Roig C, Fernández-Ávila JJ. Estudio observacional sobre interacciones farmacológicas en pacientes oncológicos ingresados. *Farm Hosp*. 2018;42(1):10-5. DOI: 10.7399/fh.10857
75. Popa MA, Wallace KJ, Brunello A, Extermann M, Balducci L. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. *J Geriatr Oncol*. 2014;5(3):307-14. DOI: 10.1016/j.jgo.2014.04.002
76. Stoll P, Kopitke L. Potential drug-drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study. *Int J Clin Pharm*. 2015;37(3):475-84. DOI: 10.1007/s11096-015-0083-6